Floatz logo

Tazemetostat

T-lymphoblastic Lymphoma

Beijing Tongren HospitalSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the T-lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
Decitabine
Mingzhi Zhang
Phase 4B
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Ifosfamide
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2CCC
Idarubicine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2CCC
Mitoxantrone
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2CCC

View all 24 →

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →